DecisionPoint Financial’s Biogen BIIB Stock Holding History

DecisionPoint Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$550	Hold	3	–	–	﹤0.01%	462
2025 Q4	$528	Hold	3	–	–	﹤0.01%	525
2025 Q3	$463	Hold	3	–	–	﹤0.01%	486
2025 Q2	$391	Buy	+3	New	+$374	﹤0.01%	502

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DecisionPoint Financial's BIIB Position: Q1 2026 in Review

DecisionPoint Financial held its Biogen (BIIB) position steady in Q1 2026 at 3 shares worth $550. The position accounts for ﹤0.01% of the portfolio, ranked #462.

DecisionPoint Financial first reported a position in BIIB in Q2 2025 and has held it in 4 quarters since. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

DecisionPoint Financial held 3 shares of Biogen worth $550 as of Q1 2026.
DecisionPoint Financial left its Biogen share count unchanged in Q1 2026.
Biogen made up ﹤0.01% of DecisionPoint Financial's portfolio in Q1 2026, its #462 holding.
DecisionPoint Financial first reported a position in Biogen in Q2 2025 and has held it in 4 quarters since.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on DecisionPoint Financial's 13F filing for Q1 2026, filed 6 May 2026.